Research programme: nitric oxide scavengers - AnorMED

Drug Profile

Research programme: nitric oxide scavengers - AnorMED

Latest Information Update: 04 Apr 2007

Price : $50

At a glance

  • Originator AnorMED
  • Developer The Institute of Cancer Research; University of Alberta; University of Calgary
  • Class
  • Mechanism of Action Nitric oxide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Inflammatory bowel diseases; Septic shock; Stroke

Most Recent Events

  • 07 Nov 2006 AnorMED has been acquired by Genzyme Corporation
  • 30 Jul 2002 AnorMED is actively seeking partnering/licensing opportunities for its nitric oxide scavengers programme
  • 29 Aug 2001 Preclinical development for Cancer in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top